JNJ 64007957

Drug Profile

JNJ 64007957

Alternative Names: JNJ-64007957; JNJ-64007959

Latest Information Update: 30 Jun 2017

Price : $50

At a glance

  • Originator Genmab; Janssen Research & Development
  • Developer Janssen Research & Development
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action B-cell maturation antigen modulators; CD3 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 16 May 2017 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (IV) (NCT03145181)
  • 11 May 2017 Janssen Research & Development plans a phase I trial for Multiple myeloma (Relapsed, Refractory metastatic disease) in USA, Spain and Sweden (NCT03145181)
  • 03 Dec 2016 Preclinical trials in Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top